Role of Interleukin-23 Circulating Levels Increase in Resected Colorectal Cancer Before and After Chemotherapy: Preliminary Data and Future Perspectives
Role of Interleukin-23 Circulating Levels Increase in Resected Colorectal Cancer Before and After Chemotherapy: Preliminary Data and Future Perspectives
复制标题
DOI：
10.1002/jcp.22653
复制
发表时间：
2011-11-01
影响因子：
5.6
通讯作者：
Gangemi, S.
中科院分区：
文献类型：
--
作者：
Adamo, V.;Franchina, T.;Gangemi, S.
IL-23是一种参与诱导Th 17细胞的异二聚体细胞因子，其表达在人肿瘤中增加。尽管已经报道内源性IL-23表达促进肿瘤发展和生长，但是使用局部和全身施用IL-23的研究已经显示其过量应用诱导抗肿瘤免疫应答。今天，IL-23被认为是肠道炎症的关键驱动因素，其在炎症反应中的作用是组织特异性的。本研究的目的是研究切除的结直肠癌（CRC）患者化疗前后IL-23循环水平的作用，相对于健康对照。2007年6月至2009年1月期间入组了25例患者，并随访至2010年。所有患者均接受化疗，主要为FOLFOX 4。招募了二十名性别和年龄匹配的健康捐赠者作为对照。采用定量酶免疫分析技术测定的IL-23血清浓度在结直肠癌切除患者中显著升高（26.02 +/- 28.63 pg/ml对比7.1 +/- 6.4 pg/ml，P < 0.001）和化疗后相对于对照（21.74 ± 23.82 pg/ml对比7.17 ± 6.43 pg/ml，P < 0.001）。化疗前也记录到增加（26.02 +/- 28.63 pg/ml vs 21.74 +/- 23.82 pg/ml，P = 0.7），但无统计学显著性。这项工作首次研究了IL-23在CRC切除和化疗中的作用，显示与疾病的严重程度，肿瘤切除和化疗治疗无关。然而，需要其他工作来更好地澄清IL-23是否可以被认为是人类CRC中的关键分子和肿瘤治疗的靶点。J.细胞。226：3032-3034，2011。(C)2011 Wiley-Liss，Inc.
Expression of IL-23, a heterodimeric cytokine involved in the induction of Th17 cells, is increased in human tumors. Although the endogenous IL-23 expression has been reported to promote tumor development and growth, the studies using local and systemic administration of IL-23 have shown that its application at the excessive amount induces antitumor immune responses. IL-23 is, today, considered the key driver of intestinal inflammation and its role in inflammatory responses is tissue-specific. The aim of this study was to investigate the role of circulating levels of IL-23 in patients with resected colorectal cancer (CRC) before and after chemotherapy, respect to healthy controls. Twenty-five patients were enrolled between June 2007 and January 2009, and followed through 2010. All patients underwent chemotherapy, mostly FOLFOX4. Twenty-sex and age-matched healthy donors were recruited as controls. IL-23 serum concentrations, measured by a quantitative enzyme immunoassay technique, were significantly higher in patients with resected CRC (26.02 +/- 28.63 pg/ml versus 7.1 +/- 6.4 pg/ml, P < 0.001) and after chemotherapy respect to controls (21.74 +/- 23.82 pg/ml versus 7.17 +/- 6.43 pg/ml, P < 0.001). An increase was documented also before chemotherapy (26.02 +/- 28.63 pg/ml versus 21.74 +/- 23.82 pg/ml, P = 0.7) but not statistically significant. This work investigated, for the first time, the role of IL-23 in CRC resection and chemotherapy, showing no correlation with the severity of disease, tumor removal, and chemotherapeutic treatment. However, other works are needed to better clarify if IL-23 could be considered a key-molecule in human CRC and a target for tumor treatment. J. Cell. Physiol. 226: 3032-3034, 2011. (C) 2011 Wiley-Liss, Inc.